Acne Medication Recalled

Contract Pharmaceuticals Limited Canada is pulling 11,350 bottles of clindamycin phosphate topical solution because of leakage around the cap stemming from a container defect, according to the September 6, 2023, US Food and Drug Administration (FDA) Enforcement Report.

The recall affects clindamycin phosphate topical solution 1%, 60-mL bottles (NDC 71428-003-60), from lot 118920 (Exp 1/24). The drug was manufactured by Contract Pharmaceuticals Limited Canada, Mississauga, Ontario, Canada, for Glasshouse Pharmaceuticals Limited Canada, Mississauga, Ontario, Canada, and was distributed throughout the United States.

Contract Pharmaceuticals Limited Canada voluntarily initiated the recall August 23, 2023. On August 29, 2023, the FDA designated the recall Class III. Per the recall classification, use of the affected medication is not likely to cause harm.

Clindamycin phosphate topical solution 1% is a prescription medication indicated in the treatment of acne vulgaris.